Apurva A. Modi - Concepedia

Author

Apurva A. Modi

National Institute of Diabetes and Digestive and Kidney Diseases ORCID

Also Known As

A. A. MODI, A. A. Modi, A. MODI, A. Modi, A.A. Modi, Apurva A Modi, Apurva A. Modi, Apurva Modi, Edward Mena

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Methodist Dallas Medical Center University of Toronto Baylor Scott & White All Saints Medical Center

About

Apurva A. Modi is an author at National Institute of Diabetes and Digestive and Kidney Diseases specializing in medicine, viral hepatitis, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.7K
2	Epidemiology	4	4	450
3	Public Health	2	2	130
4	Global Health	2	2	130
5	Health Sciences	1	1	280

Apurva A. Modi

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis Rohit Loomba, Glen Lutchman, David E. Kleiner, Alimentary Pharmacology & Therapeutics	2008	296
Increased Caffeine Consumption Is Associated With Reduced Hepatic Fibrosis Apurva A. Modi, Jordan J. Feld, Yoon Park, Hepatology NutritionFatty Liver DiseaseMetabolic SyndromeViral HepatitisHepatotoxicity	2009	280
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis† Glen Lutchman, Apurva A. Modi, David E. Kleiner, Hepatology	2007	239
Viral hepatitis and HIV in Africa. Apurva A. Modi, Jordan J. Feld PubMed Hiv CoinfectionTreatment And PreventionViral HepatitisGlobal HealthMedicine	2007	120
Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or <scp>GFR</scp> <30 ml/min Hector E. Nazario, Milka Ndungu, Apurva A. Modi Liver International	2015	107
S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders Jordan J. Feld, Apurva A. Modi, Ramy El–Diwany, Gastroenterology Interferon-stimulated Gene InductionHepatitis C NonrespondersHepatologyViral HepatitisLiver Physiology	2010	58
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis Apurva A. Modi, Hector E. Nazario, James F. Trotter, Liver Transplantation HepatologyHepatitis CCombination Antiviral TherapyViral HepatitisAntiviral Therapy	2015	40
P0802 : Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR <30 mL/min Hector E. Nazario, M. Ndungu, Apurva A. Modi Journal of Hepatology Viral HepatitisChronic Kidney DiseaseAntiviral Drug DevelopmentAntiviral TherapyHepatitis	2015	12
Realworld Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic Hepatitis C: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts Michael P. Curry, Apurva A. Modi, Surakit Pungpapong, Journal of Hepatology HepatologyHepatitis CViral HepatitisGlobal HealthAntiviral Therapy	2016	10

Page 1